|Title||PharmAbcine discloses an E-poster of updated interim result of the ongoing olinvacimab and pembrolizumab combo trial at SABCS 2020|
PharmAbcine discloses an E-poster of updated interim result of the ongoing olinvacimab and pembrolizumab combo trial at SABCS 2020
PharmAbcine presented the latest interim data from its ongoing phase Ib combination trial of olinvacimab and pembrolizumab for metastatic triple-negative breast cancer (mTNBC) patients.
As of the data cut-off date of September 2020:
- No DLT (Dose Limiting Toxicity) was observed
- 4 patients (36%) had partial response (PR) as best overall response, and 5 patients (45%) had clinical benefit (PR+SD≥24weeks)
- In the high-dose cohort, 3 patients (50%) showed PR and 4 patients (67%) received clinical benefit. 1 patient in PR showed complete response in the target lesion
Check the attached file for details.